Welcome to our dedicated page for Tempest Therapeutics news (Ticker: TPST), a resource for investors and traders seeking the latest updates and insights on Tempest Therapeutics stock.
Tempest Therapeutics, Inc. (NASDAQ: TPST) is a clinical-stage biotechnology company headquartered in Brisbane, California, developing small molecule and cell-based therapeutics with tumor-targeted and immune-mediated mechanisms to fight cancer. The TPST news feed on Stock Titan aggregates company announcements, financial updates, and regulatory milestones that shape the outlook for this oncology-focused biotech.
Investors following TPST news can expect frequent updates on the progress of Tempest’s key programs, including amezalpat (TPST-1120), a selective PPAR⍺ antagonist in development for hepatocellular carcinoma, and TPST-1495, a dual EP2/4 prostaglandin receptor antagonist being advanced for familial adenomatous polyposis. News items often highlight clinical data presentations, regulatory designations from agencies such as the FDA, EMA and China’s NMPA, and clearances or agreements for pivotal or registration-directed trials.
The company also regularly reports quarterly financial results and business updates, detailing research and development spending, cash position, and its ongoing evaluation of strategic alternatives. Capital markets activity, such as registered direct offerings of common stock, private placements of warrants, and shelf registration usage, is disclosed through press releases and corresponding SEC filings and is reflected in the TPST news stream.
In addition, Tempest issues news on strategic transactions, including its agreement to acquire dual-targeting CAR T-cell therapy programs from Factor Bioscience affiliates, which is intended to expand and diversify its clinical-stage pipeline. For market participants tracking TPST, this news page provides a centralized view of clinical, regulatory, financial, and transactional developments. Users interested in Tempest’s evolving oncology pipeline and corporate strategy can review past announcements and monitor new releases as they are published.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.